专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009129480A3 PSYCHIATRIC DISORDER THERAPY CONTROL 审中-公开
标题翻译：心理障碍治疗控制
公开(公告)号：WO2009129480A3
公开(公告)日：2010-03-25
申请号：PCT/US2009040991
申请日：2009-04-17
申请人： MEDTRONIC INC , RISE MARK T , GIFTAKIS JONATHON E , STYPULKOWSKI PAUL H , DENISON TIMOTHY J , TORGERSON NATHAN A
发明人： RISE MARK T , GIFTAKIS JONATHON E , STYPULKOWSKI PAUL H , DENISON TIMOTHY J , TORGERSON NATHAN A
IPC分类号： A61N1/36
CPC分类号： A61N1/36082 , A61B5/01 , A61B5/0488 , A61B5/08 , A61B5/0816 , A61B5/165 , A61B5/441 , A61B5/4836 , A61B5/7275
摘要： A therapy system for managing a psychiatric disorder of the patient may be controlled based on a patient mood state. Therapy may be delivered to a patient according to a therapy program, and a physiological parameter of the patient may be monitored during or after therapy delivery. The patient mood state may be determined based on the monitored physiological parameter, and the therapy delivery may be controlled based on the determined mood state. In some embodiments, the therapy delivery is stopped prior to determining the patient mood state and the therapy delivery is restarted upon detecting a negative mood state. In other embodiments, therapy delivery is delivered until a positive mood state is detected, at which point the therapy delivery may be stopped.
摘要翻译：可以基于患者情绪状态来控制用于管理患者精神障碍的治疗系统。治疗可以根据治疗程序递送到患者，并且可以在治疗递送期间或之后监测患者的生理参数。可以基于所监测的生理参数来确定患者情绪状态，并且可以基于所确定的情绪状态来控制治疗递送。在一些实施例中，在确定患者情绪状态之前停止治疗递送，并且在检测到负情绪状态时重新开始治疗递送。在其它实施方案中，递送治疗递送直到检测到正状态，此时可以停止治疗递送。

2. 发明申请

WO2009129486A3 TIMING THERAPY EVALUATION TRIALS 审中-公开
公开(公告)号：WO2009129486A3
公开(公告)日：2009-12-17
申请号：PCT/US2009041005
申请日：2009-04-17
申请人： MEDTRONIC INC , GIFTAKIS JONATHON E , RISE MARK T , STYPULKOWSKI PAUL H , DENISON TIMOTHY J
发明人： GIFTAKIS JONATHON E , RISE MARK T , STYPULKOWSKI PAUL H , DENISON TIMOTHY J
IPC分类号： A61N1/36 , A61N1/372
CPC分类号： A61N1/36135 , A61N1/0534 , A61N1/36082 , A61N1/37211 , A61N1/37247
摘要： A characteristic of a washout period following the delivery of therapy to a patient according to a therapy program may be determined based on a physiological parameter of the patient. A washout period includes the period of time during which a carryover effect from the therapy delivery dissipates. Monitoring a washout period may be useful for timing the delivery of therapy according to different therapy programs during a therapy evaluation period. For example, at least one physiological signal of the patient may be monitored to automatically determine when a washout period has ended, e.g., when stimulation and carryover effects of therapy delivery according to a first therapy program have substantially dissipated, in order to determine when therapy delivery according to a second therapy program can be initiated.

3. 发明申请

WO2009129478A3 TIMING THERAPY EVALUATION TRIALS 审中-公开
标题翻译：定时疗法评估试验
公开(公告)号：WO2009129478A3
公开(公告)日：2009-12-17
申请号：PCT/US2009040988
申请日：2009-04-17
申请人： MEDTRONIC INC , GIFTAKIS JONATHON E , RISE MARK T , STYPULKOWSKI PAUL H , DENISON TIMOTHY J
发明人： GIFTAKIS JONATHON E , RISE MARK T , STYPULKOWSKI PAUL H , DENISON TIMOTHY J
IPC分类号： A61N1/36 , A61N1/372
CPC分类号： A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3561 , A61M2205/3592 , A61M2210/0693 , A61N1/08 , A61N1/36025 , A61N1/36082 , A61N1/37211 , G06F19/3481 , G16H40/40 , G16H40/63
摘要： A characteristic of a washout period following the delivery of therapy to a patient according to a therapy program may be determined based on a physiological parameter of the patient. A washout period includes the period of time during which a carryover effect from the therapy delivery dissipates. Monitoring a washout period may be useful for timing the delivery of therapy according to different therapy programs during a therapy evaluation period. For example, at least one physiological signal of the patient may be monitored to automatically determine when a washout period has ended, e.g., when stimulation and carryover effects of therapy delivery according to a first therapy program have substantially dissipated, in order to determine when therapy delivery according to a second therapy program can be initiated.
摘要翻译：可以基于患者的生理参数确定根据治疗程序向患者递送治疗之后的清除期的特征。清除期包括治疗输送带来的滞留效应消失的时间段。在治疗评估期间，根据不同的治疗计划，监测清除期可能对于定时递送治疗有用。例如，可以监测患者的至少一个生理信号以自动确定清洗期何时结束，例如，当根据第一治疗程序的治疗递送的刺激和遗留效应已基本消散时，以便确定何时治疗可以启动根据第二疗法程序的输送。

4. 发明申请

WO2009129478A4 TIMING THERAPY EVALUATION TRIALS 审中-公开
标题翻译：时间治疗评估试验
公开(公告)号：WO2009129478A4
公开(公告)日：2010-02-04
申请号：PCT/US2009040988
申请日：2009-04-17
申请人： MEDTRONIC INC , GIFTAKIS JONATHON E , RISE MARK T , STYPULKOWSKI PAUL H , DENISON TIMOTHY J
发明人： GIFTAKIS JONATHON E , RISE MARK T , STYPULKOWSKI PAUL H , DENISON TIMOTHY J
IPC分类号： A61N1/36 , A61N1/372
CPC分类号： A61M5/14276 , A61M5/1723 , A61M2005/14208 , A61M2205/3561 , A61M2205/3592 , A61M2210/0693 , A61N1/08 , A61N1/36025 , A61N1/36082 , A61N1/37211 , G06F19/3481 , G16H40/40 , G16H40/63
摘要： A characteristic of a washout period following the delivery of therapy to a patient according to a therapy program may be determined based on a physiological parameter of the patient. A washout period includes the period of time during which a carryover effect from the therapy delivery dissipates. Monitoring a washout period may be useful for timing the delivery of therapy according to different therapy programs during a therapy evaluation period. For example, at least one physiological signal of the patient may be monitored to automatically determine when a washout period has ended, e.g., when stimulation and carryover effects of therapy delivery according to a first therapy program have substantially dissipated, in order to determine when therapy delivery according to a second therapy program can be initiated.
摘要翻译：根据治疗程序向患者输送治疗后的清洗期间的特征可以基于患者的生理参数来确定。清洗期包括治疗期间遗留结果消失的时间。在治疗评估期间，根据不同的治疗方案，监测清除期可能有助于按时交付治疗。例如，可以监测患者的至少一个生理信号，以便自动确定何时清除期已经结束，例如，当根据第一治疗程序的治疗递送的刺激和携带效应已经基本消散时，为了确定何时治疗可以启动根据第二疗法程序的递送。

5. 发明申请

WO2004034882A3 MEASURING A NEUROLOGICAL EVENT USING CLUSTERING 审中-公开
标题翻译：使用聚类测量神经病学事件
公开(公告)号：WO2004034882A3
公开(公告)日：2005-08-11
申请号：PCT/US0332940
申请日：2003-10-15
申请人： MEDTRONIC INC , FREI MARK G , OSORIO IVAN , GRAVES NINA M , SCHAFFNER SCOTT F , RISE MARK T , GIFTAKIS JONATHON E , CARLSON DAVID L
发明人： FREI MARK G , OSORIO IVAN , GRAVES NINA M , SCHAFFNER SCOTT F , RISE MARK T , GIFTAKIS JONATHON E , CARLSON DAVID L
IPC分类号： A61B20060101 , A61B5/00 , A61B5/04 , A61B5/0476
CPC分类号： A61B5/04012 , A61B5/0476 , A61B5/4094 , A61B5/7217 , A61N1/36025 , A61N1/36082 , A61N1/361 , Y10S128/92
摘要： Apparatus and method detect a detection cluster that is associated with a neurological event, such as a seizure, of nervous system disorder and update therapy parameters that are associated with a treatment therapy. The occurrence of the detection cluster is detected when the maximal ratio exceeds an intensity threshold. If the maximal ratio drops below the intensity threshold for a time interval that is less than a time threshold and subsequently rises above the intensity threshold, the subsequent time duration is considered as being associated with the detection cluster rather than being associated with a different detection cluster. Consequently, treatment of the nervous system disorder during the corresponding time period is in accordance with one detection cluster. Treatment therapy may be provided by providing electrical stimulation, drug infusion or a combination. Therapy parameters may be updated for each m successive group of applications of the treatment therapy or for each n detection cluster.
摘要翻译：装置和方法检测与神经系统疾病（例如癫痫发作），与治疗疗法相关的神经系统疾病和更新治疗参数相关联的检测簇。当最大比例超过强度阈值时，检测到簇的出现。如果最小比率在低于时间阈值的时间间隔下降到低于强度阈值，并且随后升高到强度阈值以上，则后续持续时间被认为与检测集群相关联，而不是与不同的检测集群相关联。因此，在相应时间段期间治疗神经系统疾病是根据一个检测群。可以通过提供电刺激，药物输注或组合来提供治疗治疗。可以针对治疗疗法的每个连续的应用组或每个第n个检测簇更新治疗参数。

6. 发明申请

WO2004034879A3 SCREENING TECHNIQUES FOR MANAGEMENT OF A NERVOUS SYSTEM DISORDER 审中-公开
标题翻译：用于管理神经系统疾病的筛选技术
公开(公告)号：WO2004034879A3
公开(公告)日：2004-07-22
申请号：PCT/US0332906
申请日：2003-10-15
申请人： MEDTRONIC INC , OSORIO IVAN , FREI MARK G , BHAVARAJU NARESH C , PETERS THOMAS E , GRAVES NINA M , SCHAFFNER SCOTT F , GIFTAKIS JONATHON E , RISE MARK T , WERDER JONATHAN C
发明人： OSORIO IVAN , FREI MARK G , BHAVARAJU NARESH C , PETERS THOMAS E , GRAVES NINA M , SCHAFFNER SCOTT F , GIFTAKIS JONATHON E , RISE MARK T , WERDER JONATHAN C
IPC分类号： A61B20060101 , A61B5/00 , A61B17/52 , A61F7/00 , A61N1/00 , A61N2/00
CPC分类号： A61N1/08 , A61B5/0476 , A61B5/4094 , A61B5/7275 , A61N1/36025 , A61N1/36082 , A61N1/361 , A61N1/37217
摘要： Apparatus (100) and method support a neurological event screening for a medical device. The medical device (100) assists a user in determining a configuration of the medical device for delivering an effective treatment for a nervous system disorder. The medical device detects a neurological event, such as a seizure, and reports a neurological event focus location and a neurological event spread to the user. The user may use the information to provide a configuration of a therapeutic delivery unit and associated therapy parameters. Therapeutic treatment is delivered to the patient, and the medical device is provided an indication of the patient's acceptance to the treatment. The user may modify the configuration and therapy parameters in order to achieve efficacy and acceptance. Depending upon the patient's acceptance, therapy is applied in either an open loop mode or a closed loop mode. The medical device determines whether the treatment is successful in accordance with a criterion.
摘要翻译：装置（100）和方法支持用于医疗装置的神经事件筛查。医疗装置（100）帮助用户确定医疗装置的配置以递送用于神经系统障碍的有效治疗。医疗装置检测诸如癫痫发作的神经系统事件，并向用户报告神经系统事件焦点位置和神经系统事件。用户可以使用该信息来提供治疗递送单元的配置和相关联的治疗参数。向患者传送治疗性治疗，并且向患者提供患者接受治疗的指示。用户可以修改配置和治疗参数，以达到功效和验收。根据患者的接受程度，治疗以开环模式或闭环模式应用。医疗设备根据标准确定治疗是否成功。

7. 发明申请

WO2004036370A3 CHANNEL-SELECTIVE BLANKING FOR A MEDICAL DEVICE SYSTEM 审中-公开
标题翻译：用于医疗设备系统的通道选择性保护
公开(公告)号：WO2004036370A3
公开(公告)日：2004-07-15
申请号：PCT/US0332908
申请日：2003-10-15
申请人： MEDTRONIC INC , FREI MARK G , OSORIO IVAN , RISE MARK T , GIFTAKIS JONATHON E , GRAVES NINA M , CARLSON DAVID L , JENSEN RANDY M
发明人： FREI MARK G , OSORIO IVAN , RISE MARK T , GIFTAKIS JONATHON E , GRAVES NINA M , CARLSON DAVID L , JENSEN RANDY M
IPC分类号： A61N1/08 , A61N1/32 , A61N1/36 , A61N2/00
CPC分类号： A61N1/37264 , A61N1/36146 , A61N2/00
摘要： Apparatuses and methods selectively blank a neurological channel of a medical device system (100) in the treatment of a nervous system disorder.
摘要翻译：装置和方法选择性地消除医疗装置系统（100）在治疗神经系统疾病中的神经通道。

8. 发明申请

WO2009129462A3 THERAPY TARGET SELECTION FOR PSYCHIATRIC DISORDER THERAPY 审中-公开
标题翻译：治疗精神疾病治疗方案的治疗目标选择
公开(公告)号：WO2009129462A3
公开(公告)日：2010-01-07
申请号：PCT/US2009040957
申请日：2009-04-17
申请人： MEDTRONIC INC , RISE MARK T , GIFTAKIS JONATHON E
发明人： RISE MARK T , GIFTAKIS JONATHON E
IPC分类号： A61N1/36
CPC分类号： A61N1/36082
摘要： Target tissue sites for therapy delivery to a patient may be selected based on the patient symptoms or a patient mood state. The therapy delivery may be used to manage a psychiatric disorder of the patient. Selected therapy sites may be weighted based on factors, such as the severity of the patient symptom or mood state or the type of patient symptom or mood state. In some cases, therapy delivery to the patient may be controlled based on the weighting factors. For example, the weighting factors may control the intensity of the therapy delivery or the frequency of the therapy delivery. In some examples, the weighting factors may dynamically change based on the patient's changing symptoms or mood disorders.
摘要翻译：可以基于患者症状或患者情绪状态来选择用于治疗递送给患者的靶组织位点。治疗递送可用于治疗患者的精神疾病。可以基于诸如患者症状或情绪状态的严重性或患者症状或情绪状态的类型的因素来加权所选择的治疗部位。在一些情况下，可以基于加权因子来控制对患者的治疗递送。例如，加权因子可以控制治疗递送的强度或治疗递送的频率。在一些示例中，加权因子可以基于患者的改变的症状或情绪障碍而动态地改变。

9. 发明申请

WO2004036376A2 MULTI-MODAL OPERATION OF A MEDICAL DEVICE SYSTEM 审中-公开
标题翻译：医疗器械系统的多模式操作
公开(公告)号：WO2004036376A2
公开(公告)日：2004-04-29
申请号：PCT/US0332997
申请日：2003-10-15
申请人： MEDTRONIC INC , OSORIO IVAN , FREI MARK G , RISE MARK T , SCHAFFNER SCOTT F , GRAVES NINA M
发明人： OSORIO IVAN , FREI MARK G , RISE MARK T , SCHAFFNER SCOTT F , GRAVES NINA M
IPC分类号： A61N1/08 , A61N1/36 , A61N2/00 , G06F
CPC分类号： A61N1/36025 , A61N1/08 , A61N1/36082
摘要： Apparatuses and methods support multi-modal operation of a medical device system for a nervous system disorder. The medical device system comprises an implanted component and an external component and supports a first feature and a second feature that are associated with the treatment therapy. The medical device system supports both features when the implanted component and the external component are coupled. If the external component is decoupled, the implanted component continues to support the first feature. Moreover, the embodiment may support a plurality of features during a treatment interval. Another aspect of the invention allows for modularly expanding a medical device system in order to add a feature that enhances existing functionality or that provides additional functionality. In an embodiment, a module that is associated with an external component of the medical device system supports the added feature.
摘要翻译：装置和方法支持用于神经系统障碍的医疗装置系统的多模式操作。医疗装置系统包括植入部件和外部部件，并且支撑与治疗疗法相关联的第一特征和第二特征。当植入部件和外部部件联接时，医疗装置系统支持两个特征。如果外部组件解耦，则植入组件继续支持第一个特征。此外，该实施例可以在治疗间隔期间支持多个特征。本发明的另一方面允许模块化地扩展医疗设备系统，以便添加增强现有功能或提供附加功能的特征。在一个实施例中，与医疗设备系统的外部部件相关联的模块支持附加的特征。

10. 发明申请

WO2004034997A3 MEDICAL DEVICE SYSTEM WITH RELAYING MODULE FOR TREATMENT OF NERVOUS SYSTEM DISORDERS 审中-公开
标题翻译：具有用于治疗神经系统疾病的继电器模块的医疗装置系统
公开(公告)号：WO2004034997A3
公开(公告)日：2004-10-14
申请号：PCT/US0332867
申请日：2003-10-15
申请人： MEDTRONIC INC , RISE MARK T , DONDERS ADRIANUS P , SCHAFFNER SCOTT F
发明人： RISE MARK T , DONDERS ADRIANUS P , SCHAFFNER SCOTT F
IPC分类号： A61B17/52 , A61F7/00 , A61N1/00 , A61N1/08 , A61N1/32 , A61N1/36 , A61N1/372 , A61N2/00 , A61L9/22 , A61N1/01
CPC分类号： A61N2/00 , A61N1/08 , A61N1/32 , A61N1/36082 , A61N1/36135 , A61N1/37229 , A61N1/37252
摘要： Apparatus and method facilitates communications between an implanted component (1405) and an external component (950) of a medical device system through a relaying module (1415). The medical device system provides treatment to a patient for a nervous system disorder. The relaying module (1415) (which may be worn by the patient) provides telemetry channels between the implanted component (1405) and the relaying module (1415) and between the telemetry module (1421) and the external component (950). With an implantable configuration the implanted component (1405) comprises a monitoring (20) componet, a treatment therapy unit (30), an interfacing unit (22), and a processing unit (24), and the external component comprises a programmer (23). With a hybrid configuration the implanted component (953) comprises a monitoring element (952), a treatment delivery unit (955), and an interfacing unit (951), and the external component comprises a processing unit (950). With an external configuration, the implanted component comprises a monitoring element (101) and a treatment delivery unit (107), and the external component comprises an interfacing unit (103) and a processing unit (105).
摘要翻译：装置和方法通过中继模块（1415）有助于植入部件（1405）和医疗装置系统的外部部件（950）之间的通信。医疗装置系统为患者提供神经系统障碍的治疗。中继模块（1415）（其可以由患者佩戴）在植入部件（1405）和中继模块（1415）之间以及遥测模块（1421）和外部组件（950）之间提供遥测通道。通过植入式构造，植入部件（1405）包括监控（20）部件，治疗治疗单元（30），接口单元（22）和处理单元（24），并且外部部件包括编程器（23 ）。通过混合配置，植入部件（953）包括监视元件（952），处理传送单元（955）和接口单元（951），并且外部部件包括处理单元（950）。利用外部配置，植入部件包括监视元件（101）和处理传送单元（107），并且外部部件包括接口单元（103）和处理单元（105）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式